Moderna has agreed to pay up to $2.25 billion to Arbutus Biopharma and Roivant subsidiary Genevant Sciences, ending a years-long legal battle over the lipid nanoparticle (LNP) technology critical to its mRNA COVID-19 vaccines. The settlement includes $950 million upfront in July 2026, with an additional $1.3 billion contingent on the outcome of a separate legal appeal.

The dispute centered on the fatty shells that deliver mRNA into human cells — a technology pioneered by Arbutus that Moderna used without a license. Under the deal, Moderna receives a global non-exclusive license for LNP delivery in infectious-disease mRNA vaccines and will owe no future royalties. Moderna shares jumped over 15% on the news, driving the stock up more than 95% year-to-date in 2026.

Arbutus and Genevant still have a separate ongoing patent lawsuit against Pfizer and BioNTech over the same LNP technology used in their competing COVID vaccine.